Form 4: Savara CMO Sells Shares for Tax Obligations

Savara Inc.'s Chief Medical Officer, Yasmine Wasfi, disposed of 21,992 common shares at $6.37 each to cover tax liabilities from vested restricted stock units.

Summary

• Yasmine Wasfi, Chief Medical Officer of Savara Inc. (SVRA), reported a transaction involving common stock.
• On December 4, 2025, Wasfi disposed of 21,992 shares of common stock.
• The disposal was a 'net share settlement' to satisfy tax liability arising from the vesting of previously awarded restricted stock units (RSUs).
• The shares were disposed of at a price of $6.37 per share.
• Following this transaction, Wasfi beneficially owns 168,008 shares of Savara Inc. common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common occurrence for executive compensation and does not reflect a change in company fundamentals or management's outlook.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction represents a routine insider filing common in the biotechnology and pharmaceutical industries, where executive compensation often includes restricted stock units that vest over time. The disposal of shares to cover tax obligations upon vesting is a standard practice and does not typically reflect a discretionary sale based on management's view of the company's prospects.

Stakeholder Impact

• Shareholders may note the reduction in insider holdings, but given it's a tax-related sale from RSU vesting, it is unlikely to signal a change in management confidence or company performance.

Key Dates

Keywords

Savara Inc., SVRA, Form 4, Insider Transaction, Chief Medical Officer, Yasmine Wasfi, Restricted Stock Units, Tax Withholding, Equity Compensation